Company Overview and News

1
The confidence conundrum

2018-10-02 nzherald.co.nz
The conundrum at the heart of the Kiwi economy right now is this: despite the highest level of quarterly growth seen in the past two years, business confidence continues to sink.
SKLUY SKL WM

 
NZ shares fall as A2 Milk extends decline

2018-09-27 nzherald.co.nz
New Zealand shares fell as A2 Milk Co extended its decline since its chief executive sold down her holding. Rising bond yields also dimmed the lustre of property stocks.
AIA FBU FCREY SPKKY EBOSY NZTCY SPK NZTCF ACKDF FRCEF EBO AUKNY KWIPF AOTUF EBOSF SKC AIA FBU THL VTHPF SKLUY SKL MEZ EBO

 
Synlait Milk leads gains before trading suspended

2018-08-28 nzherald.co.nz
New Zealand shares barely traded today as the system was down for most of the day due to operational issues.
AIR THO ANZFY AIZ SKT SYKWF THL ANZLY SKKTY SKLUY SKL ANZFF SML

 
NZ shares hit record; Synlait, a2 gain while Sky TV, Z Energy drop

2018-08-27 nzherald.co.nz
New Zealand shares hit a record, led higher by Synlait Milk and a2 Milk Co while Sky Network Television continued Friday's decline.
MQBKY AIA MHI ZNRGF MXRHY MCQEF ACKDF ZEL AUKNY SKT ZNZ SYKWF AIA SKKTY SKLUY SKL MQG SML MXRHF

 
NZ shares gain as investors take stock in earnings season

2018-08-17 nzherald.co.nz
New Zealand shares rose as investors took stock in a brief lull to the domestic corporate earnings season, with Skellerup Holdings extending yesterday's gain to break a new record.
CEN AIR NZTCF RYM ACKDF ANZFY AUKNY AIZ COENF GNE AOTUF SKC PPSHY CEN SNZ SKL GEL AIA RHCGF SPKKY NZTCY SPK COENY AIA THL ANZLY RYHTY SKLUY ANZFF GNE MEZ

 
NZ shares rise as Skellerup posts record profit

2018-08-16 nzherald.co.nz
New Zealand shares rose, led higher by a record profit from Skellerup Holdings, as investors focused more on domestic earnings than volatility in global markets. Precinct Properties New Zealand also gained.
CEN AIA FBU FCREY SPKKY NZTCY SPK NZTCF ACKDF FRCEF AUKNY COENY COENF AOTUF SKC AIA FBU CEN SKLUY SKL PFGTF SML

 
NZ shares rise as earnings continue

2018-08-15 nzherald.co.nz
New Zealand shares rose as earnings season continued to deliver mixed results. NZX was among gainers on the day after delivering a special dividend while Heartland Bank fell on its increased bad debt provisioning.
AIA SPKKY NZTCY SPK NZTCF WDT ACKDF AUKNY SKT AOTUF SYKWF AIA SKKTY SKLUY SKL MEZ WFVLF SML

 
NZ shares up; TradeMe and A2 gain

2018-08-10 nzherald.co.nz
New Zealand shares gained on continued market strength from the weaker Kiwi dollar, led higher by Trade Me Group and A2 Milk Co, while Fonterra Shareholders Fund dropped as its expected final dividend was removed.
TME TRMEF FBU FBU FCREY TME SKLUY SKL TDMEY FRCEF FTRRF

 
NZ shares drop, led lower by Synlait Milk

2018-07-11 nzherald.co.nz
New Zealand shares dropped, led by Synlait Milk and Infratil, while Gentrack Group gained and Ryman Healthcare hit a record high.
KTHDY RHCGF RYHTY SKLUY SKL GTK RYM KMD SML KMD

 
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 830573101